MARKET

ICAD

ICAD

Icad Inc
NASDAQ
2.150
+0.020
+0.94%
After Hours: 2.150 0 0.00% 16:00 09/29 EDT
OPEN
2.130
PREV CLOSE
2.130
HIGH
2.180
LOW
2.060
VOLUME
52.02K
TURNOVER
0
52 WEEK HIGH
11.85
52 WEEK LOW
1.970
MARKET CAP
54.47M
P/E (TTM)
-4.1626
1D
5D
1M
3M
1Y
5Y
Insider Sell: Icad
Insider Sell: Icad
MT Newswires · 09/14 16:23
iCAD To Participate in The Lake Street Capital Markets 6th Annual Best Ideas Growth (BIG6) Conference on September 14, 2022
NASHUA, N.H., Sept. 07, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the Lake Street Capital Markets, 6th...
GlobeNewswire · 09/07 12:00
iCAD (NASDAQ:ICAD) shareholders have endured a 76% loss from investing in the stock a year ago
The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...
Simply Wall St. · 09/05 11:34
JMP Securities Maintains Market Outperform on icad, Lowers Price Target to $7
JMP Securities analyst David Turkaly maintains icad (NASDAQ:ICAD) with a Market Outperform and lowers the price target from $13 to $7.
Benzinga · 09/01 11:25
JMP Securities Adjusts icad's Price Target to $7 From $13, Maintains Market Outperform Rating
JMP Securities Adjusts icad's Price Target to $7 From $13, Maintains Market Outperform Rating
MT Newswires · 09/01 08:32
iCAD Customers in the U.S. and Europe Increasingly Adopting Company’s Full Suite of Breast AI Technologies via Subscription Model
Flexible subscription model accelerates deployment of iCAD’s Breast AI Suite, the only complete solution designed to comprehensively address today’s top imaging challengesNASHUA, N.H., Aug. 29, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global m...
GlobeNewswire · 08/29 12:00
After Plunging 29.6% in 4 Weeks, Here's Why the Trend Might Reverse for Icad (ICAD)
Icad (ICAD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks · 08/19 13:35
--Lake Street Adjusts icad Price Target to $8 From $13, Maintains Buy Rating
--Lake Street Adjusts icad Price Target to $8 From $13, Maintains Buy Rating
MT Newswires · 08/11 11:05
More
About ICAD
iCAD, Inc. is a global medical technology company, which provides cancer detection and therapy solutions. The Company operates through two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). In the Detection segment, the Company’s solutions include advanced image analysis and workflow solutions enables healthcare professionals to serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, and a comprehensive range of artificial intelligence and computer aided detection (CAD) systems and workflow solutions for two-dimension(2D) and third dimension (3D) mammography, magnetic resonance imaging (MRI) and computed tomography (CT). In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.

Webull offers kinds of iCAD Inc stock information, including NASDAQ:ICAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICAD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ICAD stock methods without spending real money on the virtual paper trading platform.